Have you ever tried to paint a room in the dark? Probably not, right?
Why would anyone go through the trouble of getting the supplies and putting in the effort to attempt a job well done if they couldn’t see their progress along the way? Just the same, why would anyone turn their career over to the annual performance review process?
CYCLE FOR SURVIVAL 2018
Every dollar represents hope, strength, and a lasting impact!
With the holiday season in full swing, it’s hard not to reflect on this past year and realize how thankful Veristat is to play such an instrumental role in the world of clinical research.
Veristat aspires to make a difference, every day!
As the weather gets colder and we find ourselves in the holiday season, the employees of Veristat decided to make a difference by helping others in their local communities.
A Recap of the New York Medidata NEXT Event: Where Science Meets Technology Meets the Future
Kathleen Boruchowski, Associate Director of Data Management, attended the Medidata NEXTconference in New York City on November 8-10. The conference, which has many global locations throughout the year, offered Medidata’s customers a front row seat to learn how data, insights, and technology are transforming the clinical trials industry and ultimately accelerating the hope for patients desperately seeking new treatment options.
Veristat Hosts Its 2017 Annual International Company Meeting
Last week, Veristat gathered nearly 200 team members from multiple countries for our annual International Company Meeting. What better a place to host our team meeting than Gillette Stadium, home to the five-time Superbowl championship winning New England Patriots.
Explore What We Learned at the 8th Clinical Quality Oversight Forum
Veristat’s Senior Director of Corporate Compliance attended the 8th Clinical Quality Oversight Forum, an annual conference which took place 10-13 October 2017 in Philadelphia, PA.
In pharmaceutical clinical trials, considering competing risk analyses is highly important. Competing risks are events that may occur and prevent the evaluation of a specific primary endpoint, in turn biasing risk estimations or drug efficacy.